natgillin/translations-raw huggingface dataset:
Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)
Alogene T-stanice genetski modificirane retrovirusnim vektorom koji kodira skraćeni oblik ljudskog receptora za faktor rasta živaca niskog afiniteta (ΔLNGFR) i timidin kinazu virusa herpes simplex tip 1 (HSV-TK Mut2).
Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2).
Alogene T-stanice genetski modificirane retrovirusnim vektorom koji kodira skraćeni oblik ljudskog receptora za faktor rasta živaca niskog afiniteta (ΔLNGFR) i timidin kinazu virusa herpes simplex tip 1 (HSV-TK Mut2).
Allograft transplant patients maintained on twice daily Prograf capsules dosing requiring conversion to once daily Advagraf should be converted on a 1:1 (mg:mg) total daily dose basis.
U bolesnika s alogenim presatkom koji uzimaju kapsule Prografa dvaput na dan, a moraju prijeći na liječenje Advagrafom koji uzimaju jedanput na dan, omjer ukupne dnevne doze mora ostati 1:1 (mg:mg).
Allopurinol 300 /
Alopurinol 300 /
Allopurinol and other xanthine oxidase inhibitors decrease the rate of catabolism of
Alopurinol i drugi inhibitori ksantin oksidaze smanjuju brzinu katabolizma 6-merkaptopurina.
allopurinol or febuxostat (used to treat gout)
alopurinol ili febuksostat (za liječenje gihta)
allopurinol, probenecid, sulfinpyrazone (to treat gout)
alopurinol, probenecid, sulfinpirazon (za liječenje uloga)
Allow 10-15 minutes for the vial to warm to room temperature (15C - 25C).
Ostavite bočicu 10-15 min da se zagrije na sobnu temperaturu (15C - 25C).
Allow 10-15 minutes for the vial to warm to room temperature (15C - 25C).
Ostavite bočicu 10-15 minuta da se zagrije na sobnu temperaturu (15C - 25C).
Allow any foam to settle.
Ako se stvori pjena, pričekajte da nestane.
Allow refrigerated product to come to room temperature before use.
Pričekajte da lijek iz hladnjaka postigne sobnu temperaturu prije upotrebe.
Allow the alcohol to dry on the skin before fixing the administration system into place.
Pričekajte da se alkohol na koži osuši prije nego što pričvrstite sustav za primjenu.
Allow the application site to dry before permitting contact with such materials.
Pričekajte da se mjesto aplikacije osuši prije nego omogućite dodir životinje s takvim površinama.
Allow the application site to dry before permitting contact with such materials.
Treba omogućiti da se mjesto aplikacije osuši prije nego se dođe u doticaj s takvim materijalima.
Allow the area to dry for 15 minutes.
Pustite da se to područje suši 15 minuta.
Allow the gel to dry for three to five minutes before covering a treated area with loose clothing.
Ostavite gel tri do pet minuta da se osuši prije nego što pokrijete liječeno područje laganom odjećom.
Allow the injection area to dry.
Pustite da se područje injiciranja osuši.
Allow the medicine to reach room temperature:
Omogućite da lijek postigne sobnu temperaturu:
Allow the pen to sit at room temperature outside the box for 30 minutes before use.
Izvadite brizgalicu iz kutije da odstoji na sobnoj temperaturi 30 minuta prije uporabe.
Allow the pen to sit at room temperature outside the box for 30 minutes before use.
Izvadite štrcaljku iz kutije da odstoji na sobnoj temperaturi 30 minuta prije uporabe.
Allow the pre-filled pen to adjust to room temperature
Pustite napunjenu brizgalicu da dosegne sobnu temperaturu
Allow the pre-filled syringe to reach room temperature.
Ostavite napunjenu štrcaljku da postigne sobnu temperaturu.
Allow the pre-filled syringe to reach room temperature.
Prije injiciranja neka se napunjena štrcaljka ugrije na sobnu temperaturu.
Allow the premix vial to stand for 5 minutes at room temperature (below 25°C) and then check that the solution is homogenous and clear (foaming is normal even after 5 minutes due to the presence of polysorbate 80 in the formulation).
Ostavite bočicu s pripremljenom otopinom koncentrata na sobnoj temperaturi (ispod 25°C) oko 5 minuta, a zatim provjerite je li otopina homogena i bistra (pojava pjene je uobičajena i nakon 5 minuta zbog polisorbata 80 u sastavu).
Allow the premix vial to stand for 5 minutes at room temperature (below 25C) and then check that the solution is homogenous and clear (foaming is normal even after 5 minutes due to the presence of polysorbate 80 in the formulation).
Ostavite bočicu s pripremljenom otopinom koncentrata na sobnoj temperaturi (ispod 25 oC) oko 5 minuta, a zatim provjerite je li otopina homogena i bistra (pojava pjene je uobičajena i nakon 5 minuta zbog polisorbata 80 u sastavu).
Allow the pump to fully reflate before administering consecutive sprays.
Pričekajte da se pumpica
Allow the skin to dry before injecting.
Pustite da se koža osuši prije injiciranja.
Allow the skin to dry before injecting.
Pustite da se koža osuši prije ubrizgavanja.
Allow the solution to reach room temperature before injection or warm the syringe between your palms.
Pustite da otopina postigne sobnu temperaturu prije primjene ili zagrijte štrcaljku među dlanovima.
Allow the solution to reach room temperature before injection or warm the syringe between your palms.
Pustite da otopina prije primjene poprimi sobnu temperaturu ili zagrijte štrcaljku među dlanovima.
Allow the solvent to flow into the powder vial.
Pustite otapalo da teče u bočicu s praškom.
Allow the sterile solvent to reach room temperature (15–25 C).
Pričekati da otapalo dostigne sobnu temperaturu (15-25°C).
Allow the sterile solvent to reach room temperature (15–25 C).
Pričekati da otapalo postigne sobnu temperaturu ( 15-25°C).
Allow the syringe to air-dry and store with the bottle. syringe.
Pustite da se štrcaljka prirodno osuši i spremite je s bocom.
Allow the syringe to sit at room temperature outside the box for 25 to 30 minutes before use
Prije primjene izvadite štrcaljku iz kutije i pričekajte 25-30 minuta da se ugrije na sobnu temperaturu
Allow the syringe to sit at room temperature outside the box for 30 minutes before use.
Izvadite štrcaljku iz kutije da odstoji na sobnoj temperaturi 30 minuta prije uporabe.
Allow the vaccine to reach a temperature of 15 °C – 25 °C. Shake well before use.
Pričekati da cjepivo dostigne temperaturu od 15°C - 25°C. Dobro protresti prije upotrebe.
Allow the vaccine to reach a temperature of 15 C to 25 C before administration.
Prije primjene pričekajte da cjepivo dostigne temperaturu od 15 C do 25 C.
Allow the vaccine to reach room temperature (15-25˚C) before administration.
Prije primjene pričekajte da cjepivo dostigne sobnu temperaturu (15 ˚C-25 ˚C).
Allow the vaccine to reach room temperature (15-25˚C) before administration.
Prije primjene pričekajte da cjepivo dostigne sobnu temperaturu (15-25 C).
Allow the vaccine to reach room temperature (15–25 ºC) before administration.
Prije primjene pričekajte da cjepivo dosegne sobnu temperaturu (15 ˚C - 25 ˚C).
Allow the vaccine to reach room temperature (15–25 ºC) before administration.
Prije primjene pričekajte da cjepivo dosegne sobnu temperaturu (15 ˚C-25 ˚C).
Allow the vaccine to reach room temperature (15–25 ºC) before administration.
Prije primjene pričekajte da cjepivo dostigne sobnu temperaturu (15 ˚C-25 ˚C).
Allow the vaccine to reach room temperature before use.
Prija davanja cjepivo treba biti na sobnoj temperaturi.
Allow the vial to reach room temperature and inspect the liquid phase for particulate matter or precipitates before resuspension.
Pričekajte da se bočica zagrije na sobnu temperaturu i prije ponovne priprave suspenzije provjerite da se u tekućoj fazi ne nalaze čestice ili precipitat.
Allow the vial to sit at room temperature (15C - 25C) during reconstitution, gently swirling the vial for 60 seconds every 5 minutes until the powder is dissolved.
Ostavite bočicu da stoji na sobnoj temperaturi (15C - 25C) tijekom rekonstitucije, nježno vrteći bočicu 60 sekundi, svakih 5 minuta, dok se prašak ne otopi.
Allow the vial with the concentrate to stand for 5 minutes at room temperature and check if the solution is homogenous and clear.
Ostavite koncentrat u bočici 5 minuta pri sobnoj temperaturi i provjerite je li otopina homogena i bistra.
Allow the vials to dry before opening the Mix2Vial (device pack), then follow the instructions given below.
Pričekajte da se bočice osuše prije nego što otvorite Mix2Vial (pribor za primjenu), a zatim slijedite upute u nastavku.
Allow to reach room temperature.
Prije injiciranja neka se napunjena brizgalica ugrije na sobnu temperaturu.
Allow to stand for about 15 minutes at room temperature to obtain a clear to opalescent solution.
Pustite da odstoji oko 15 minuta na sobnoj temperaturi kako biste dobili bistru do opalescentnu otopinu.
Allow to stand for about 15 minutes at room temperature.
Pustite da odstoji oko 15 minuta na sobnoj temperaturi.
Allow vials to reach room temperature.
Prije uporabe bočice trebaju dosegnuti sobnu temperaturu.
Allow your pen to warm at room temperature before using.
Dopustite da se prije uporabe brizgalica ugrije na sobnu temperaturu.
allows continued monitoring of the benefit/risk balance of the medicinal product.
omogućuje kontinuirano praćenje omjera koristi i rizika lijeka.
allows continued monitoring of the benefit/risk balance of the medicinal product.
Time se omogućuje kontinuirano praćenje omjera koristi i rizika lijeka.
allows continued monitoring of the benefit/risk balance of the medicinal product.
Time se omogućuje kontinuirano praćenje omjera koristi i rizika tog lijeka.
allows continued monitoring of the benefit/risk balance of the medicinal product.
Za otkrivanje mogućih aritmija neophodno je kardiovaskularno praćenje.
Allura Red AC (E129) (see section 2)
Allura Red AC (E129) (vidjeti dio 2.)
Allée de la Recherche 60 (address only for outer carton)
Allée de la Recherche 60 (adresa samo za kutiju)
Allée de la Recherche 60 B-1070 Brussels BELGIUM
Allée de la Recherche 60 B-1070 Brussels BELGIJA
Allée de la Recherche 60 B-1070 Bruxelles Belgium
Allée de la Recherche 60 B-1070 Bruexelles Belgija
Almac Pharma Services
Almac Pharma Service
Almac Pharma Services
AlmacPharma Services
Almac Pharma Services Limited, Almac House, 20 Seagoe Industrial Estate, Craigavon, BT63 5QD, United Kingdom
Almac Pharma Services Limited, Almac House, 20 Seagoe Industrial Estate, Craigavon, BT63 5QD, Velika Britanija
almeterol (used to treat asthma)
almeterol (primjenjuje se za liječenje astme)
almeterol is not recommended (see section 4.5); rivaroxaban is not recommended (see section 4.5).
almeterolom nije preporučljiva (vidjeti dio 4.5); rivaroksabanom nije preporučljiva (vidjeti dio 4.5).
almeterol is not recommended (see section 4.5); rivaroxaban is not recommended (see section 4.5).
almeterolom se ne preporučuje (vidjeti dio 4.5); rivaroksabanom se ne preporučuje (vidjeti dio 4.5).
almeterol, a medicine used to treat asthma
almeterol, lijek koji se primjenjuje za liječenje astme
Almirall, S.A.
Almirall S.A.
Almirall, S.A.
Almirall, S.A
Almost 3,000 of the patients in the studies had essential thrombocythaemia, defined as a platelet count of more than 600 million/ml.
Gotovo 3 000 bolesnika koji su sudjelovali u studijama imalo je esencijalnu trombocitemiju, definiranu na osnovi razine trombocita veće od 600 milijuna/ml.
Almost 4,000 patients from these 5 studies went on to enter studies looking at the long-term effects of RoActemra treatment and results showed that response to RoActemra is maintained for at least two years.
Gotovo 4 000 bolesnika uključenih u ovih pet ispitivanja kasnije je sudjelovalo u ispitivanjima kojima su proučavani dugoročni učinci terapije lijekom RoActemra, a rezultati su pokazali da se odgovor na lijek RoActemra zadržava barem dvije godine.
Almost 80% of an oral dose of esomeprazole is excreted as metabolites in the urine, the remainder in the faeces.
Gotovo 80% peroralne doze esomeprazola izlučuje se mokraćom u obliku metabolita, a ostatak fecesom.
Almost all fevers were mild or moderate (<39.5°C) and transient (duration of ≤2 days). (See section 4.8).
Gotovo svi slučajevi vrućice bili su blagi ili umjereni (<39,5°C) te prolazni (trajali su ≤2 dana). (vidjeti dio 4.8).
Almost all HSR to abacavir include fever and/or rash .
Gotovo sve reakcije preosjetljivosti na abakavir bit će praćene vrućicom i/ili osipom.
Almost all patients had also received drugs known as azathioprine or 6-mercaptopurine in addition to TNF-blockers.
Skoro svi bolesnici također su uzimali lijekove azatioprin ili 6-merkaptopurin s TNF-blokatorom.
Almost all patients had also received drugs known as azathioprine or 6-mercaptopurine in addition to TNF-blockers..
Gotovo svi bolesnici također su uzimali i lijekove azatioprin ili 6-merkaptopurin s TNF-blokatorima.
Almost all patients had received treatment with AZA or
Gotovo svi ti bolesnici liječeni su azatioprinom (AZA) ili
Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, ACE inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates).
Gotovo su svi ispitanici (95%) uzimali kardiovaskularne lijekove (beta blokatore, ACE inhibitore, antagoniste angiotenzina II, blokatore kalcijevih kanala, nitrate, diuretike, aspirin, statine, fibrate).
Almost all subjects who were treated with subcutaneous icatibant in clinical trials developed reactions at the site of injection (characterised by skin irritation, swelling, pain, itchiness, erythema, burning sensation).
Gotovo svi ispitanici koji su supkutano primili ikatibant u kliničkim ispitivanjima razvili su reakcije na mjestu uboda injekcije (karakteriziraju ih iritacija kože, oticanje, bol, svrbež, eritem, osjećaj žarenja).
Almost all the patients in the studies had the virus cleared from their blood after 12 or 24 weeks.
U gotovo svih bolesnika u 6 glavnih ispitivanja virus je očišćen iz krvi nakon 12 tjedana ili 24 tjedna.
Almost all the patients with these genotypes treated in studies had the virus cleared from their blood.
Kod gotovo svih bolesnika s tim genotipovima virusa koji su liječeni u ispitivanju virus se iščistio iz krvi.
Almost fainting (presyncope)
gotovo nesvjestica (presinkopa)
Almost half (45.8 %) of the RE-LY patients had a CrCL > 50-< 80 mL/min.
Gotovo polovina (45,8 %) ispitanika imala je CrCL > 50-< 80 mL/min.
Almost the entire 64CuCl2 rapidly leaves the blood and enters the liver and kidney.
Gotovo cijela količina 64CuCl2 brzo prelazi iz krvi u jetru i bubrege.
aLOCF: Last observation (prior to or o bAll randomised subjects who took at l double-blind period cLeast squares mean adjusted for basel
aLOCF (Last observation carried for povećanja doze inzulina, ako je potre bSvi randomizirani bolesnici koji su t ispitivanog lijeka u dvostruko slijepo cSrednja vrijednost dobivena metodo peroralnih lijekova za snižavanje razi
aLOCF: Last observation (prior to or on the date of the first insulin up-titration, if needed) carried forward bAll randomised subjects who took at least one dose of double-blind study medicinal product during the short-term double-blind period cLeast squares mean adjusted for baseline value and presence of oral glucose-lowering medicinal product
aLOCF (Last observation carried forward): Prijenos posljednjih zabilježenih vrijednosti (prije ili na dan prvog povećanja doze inzulina, ako je potrebno) bSvi randomizirani bolesnici koji su tijekom kratkoročnog dvostruko slijepog razdoblja uzeli barem jednu dozu ispitivanog lijeka u dvostruko slijepom ispitivanju cSrednja vrijednost dobivena metodom najmanjih kvadrata prilagođena za početnu vrijednost i prisutnost peroralnih lijekova za snižavanje razine glukoze
aLOCF: Last observation (prior to rescue for rescued subjects) carried forward bAll randomised subjects who took at least one dose of double-blind study medication during the short-term double-blind period cLeast squares mean adjusted for baseline value
aLOCF: Prijenos posljednjih zabilježenih vrijednosti (prije primjene terapije za nužnu regulaciju neregulirane glikemije u ispitanika kojima je ona primijenjena) (Last observation carried forward) bSvi randomizirani ispitanici koji su tijekom kratkoročnog dvostruko slijepog razdoblja uzeli barem jednu dozu ispitivanog lijeka u dvostruko slijepom ispitivanju cSrednja vrijednost najmanjih kvadrata prilagođena za početnu vrijednost
aLOCF: Last observation carried forward bRandomised and treated subjects with baseline a cLeast squares mean adjusted for baseline value dNon-inferior to glipizide + metformin
aLOCF: Prijenos posljednjih zabilježenih vrijednosti (Last observation carried forward) bRandomizirani i liječeni ispitanici kod kojih je izmjerena djelotvornost na početku liječenja i barem jednom nakon početka liječenja cSrednja vrijednost najmanjih kvadrata prilagođena za početnu vrijednost dNeinferiornost u odnosu na glipizid + metformin
aLOCF: Last observation carried forward bRandomised and treated subjects with baseline and at cLeast squares mean adjusted for baseline value dNon-inferior to glipizide + metformin
aLOCF: Prijenos zadnjih zabilježenih vrijednosti (Last bRandomizirani i liječeni ispitanici kod kojih je mjeren nakon početne vrijednosti cSrednja vrijednost dobivena metodom najmanjih kvad dNeinferiornost u odnosu na glipizid + metformin
aLOCF: Last observation carried forward bRandomised and treated subjects with baseline and at least 1 post-baseline efficacy measurement cLeast squares mean adjusted for baseline value dNon-inferior to glipizide + metformin
aLOCF: Prijenos posljednjih zabilježenih vrijednosti (Last observation carried forward) bRandomizirani i liječeni ispitanici kod kojih je izmjerena djelotvornost na početku liječenja i barem jednom nakon početka liječenja cSrednja vrijednost najmanjih kvadrata prilagođena za početnu vrijednost dNeinferiornost u odnosu na glipizid + metformin
aLOCF: Last observation carried forward bRandomised and treated subjects with baseline and at least 1 post-baseline efficacy measurement cLeast squares mean adjusted for baseline value dNon-inferior to glipizide + metformin
aLOCF: Prijenos zadnjih zabilježenih vrijednosti (Last observation carried forward) bRandomizirani i liječeni ispitanici kod kojih je mjerena djelotvornost pri početnoj vrijednosti i barem jednom nakon početne vrijednosti cSrednja vrijednost dobivena metodom najmanjih kvadrata prilagođena za početnu vrijednost dNeinferiornost u odnosu na glipizid + metformin
Alogliptin 25 mg once daily (n=128)
Alogliptin 25 mg jedanput na dan
Alogliptin 25 mg once daily with a sulphonylurea (n=197)
Alogliptin 25 mg jedanput na dan sa sulfonilurejom
Alogliptin 25 mg once daily with a thiazolidinedione  metformin or a sulphonylurea (n=195)
Alogliptin 25 mg jedanput na dan s tiazolidindionom + metformin ili sulfonilureja
Alogliptin 25 mg once daily with a thiazolidinedione  metformin or a sulphonylurea (n=195)
Alogliptin 25 mg jedanput na dan s tiazolidindionom±metformin ili sulfonilureja
Alogliptin 25 mg once daily with insulin + metformin (n=126)
Alogliptin 25 mg jedanput na dan s inzulinom + metforminom
Alogliptin 25 mg once daily with metformin (n=203)
Alogliptin 25 mg jedanput na dan s metforminom
Alogliptin 25 mg once daily with metformin (n=203)
Alogliptin 25 mg jedanput na dan s metforminom (n=203)
Alogliptin 25 mg once daily with metformin vs a sulphonylurea + metformin
Alogliptin 25 mg jedanput na dan s metforminom naspram sulfonilureja+metformin
Alogliptin 25 mg once daily with pioglitazone + metformin vs titrating pioglitazone + metformin
Alogliptin 25 mg jedanput na dan s pioglitazonom + metformin naspram titrirani pioglitazon + metformin
Alogliptin 25 mg once daily with pioglitazone  metformin or a sulphonylurea (n=195)
Alogliptin 25 mg jedanput na dan s pioglitazonom + metformin ili sulfonilurejom
Alogliptin and metformin are substantially excreted by the kidney.
Alogliptin i metformin se u znatnoj mjeri izlučuju putem bubrega.
Alogliptin as add-on therapy to a thiazolidinedione
Alogliptin kao dodatna terapija tiazolidindionu
Alogliptin as add-on therapy to a thiazolidinedione with metformin
Alogliptin kao dodatna terapija tiazolidindionu i metforminu
Alogliptin as add-on therapy to insulin (with or without metformin)
Alogliptin kao dodatna terapija inzulinu (s ili bez metformina)
Alogliptin as add-on therapy to metformin with a thiazolidinedione
Alogliptin kao dodatak terapiji metforminu s tiazolidindionom
Alogliptin as add-on therapy to metformin with insulin
Alogliptin kao dodatna terapija metforminu i inzulinu
Alogliptin as add-on therapy to pioglitazone with metformin
Alogliptin kao dodatak terapiji pioglitazonu s metforminom
alogliptin belongs to a group of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors).
alogliptin pripada skupini lijekova pod nazivom DPP-4 inhibitori (inhibitori dipeptidil peptidaze-4).
Alogliptin does not undergo extensive metabolism, 60-70% of the dose is excreted as unchanged drug in the urine.
Alogliptin ne prolazi ekstenzivni metabolizam te se 60-70% doze izluči kao neizmijenjen lijek u mokraći.
Alogliptin does not undergo extensive metabolism, 60-70% of the dose is excreted as unchanged drug in the urine.
Alogliptin ne prolazi ekstenzivni metabolizam te se 60-70% doze izluči kao nepromijenjen lijek u mokraći.
Alogliptin has no or negligible influence on the ability to drive and use machines.
Alogliptin ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9.
Alogliptin je potentan i visoko selektivan inhibitor DPP-4, sa > 10 000 puta većom selektivnošću za DPP-4 nego za druge srodne enzime, uključujući DPP-8 i DPP-9.
Alogliptin works to increase the levels of insulin in the body after a meal and decrease the amount of sugar in the body. metformin belongs to a group of medicines called biguanides which also help to lower blood sugar by lowering the amount of sugar made in the liver and helping insulin to work more effectively.
Alogliptin djeluje tako da podiže razine inzulina u tijelu nakon obroka i smanjuje količinu šećera u krvi. metformin pripada skupini lijekova pod nazivom bigvanidi i također pomaže sniziti šećer u krvi smanjujući količinu šećera što se stvara u jetri i pomažući inzulinu da učinkovitije djeluje.
Alogliptin works to increase the levels of insulin in the body after a meal and decrease the amount of sugar in the body. pioglitazone belongs to a group of medicines called thiazolidinediones.
Alogliptin djeluje tako da podiže razine inzulina u tijelu nakon obroka i smanjuje razinu šećera u krvi. pioglitazon pripada skupini lijekova pod nazivom tiazolidindioni.
Alogliptin/pioglitazone
Alogliptin/pioglitazon
alone
bez efavirenza
alone as basal insulin
amostalno kao bazalni inzulin
alone or in combination with other fat-lowering medicines in patients who cannot tolerate or cannot be given statins. adults and children aged 12 years and over who have ‘homozygous familial hypercholesterolaemia’ (a severe form of hypercholesterolaemia caused by a genetic abnormality inherited from both parents).
U odraslih osoba i djece u dobi od 12 godina i starijih koji imaju „heterozigotnu obiteljsku hiperkolesterolemiju” (težak oblik hiperkolesterolemije uzrokovan genetskom abnormalnošću
alone or together with the medicines pegylated liposomal doxorubicin or dexamethasone, for patients whose disease is worsening (progressive) after receiving at least one prior treatment and for whom blood stem cell transplantation was not successful or is unsuitable.
amostalno ili zajedno sa lijekom pegiliranim liposomalnim doksorubicinom ili deksametazonom, u bolesnika kod kojih je došlo do pogoršanja bolesti (progresije) nakon posljednje terapije te su prethodno prošli ili nisu predviđeni za transplantaciju krvotvornih matičnih stanica.